Amarin Corp Plc (AMRN)

[retinadoc]

Mitigate question: Will the trial be able to answer the question of MACE risk reduction over the six months following COVID infection? Since the trial was initiated, we have new data that clearly says: 1) Everyone is at far greater risk for a major CV event in the six months after COVID infection. Including young patients with no CV risk.
2) From AHA last weekend we now know that anticoagulation, which is the biggest gun in the prevention of CV events, made no difference in decreasing these events.

https://www.medpagetoday.com/meetingcoverage/aha/101639

That leaves us with nothing as far as I know. If Xeralto failed, aspirin will almost certainly fail as well. I suspect that the Mitigate results will be similar to the smoking study that showed pure EPA took smokers back to the risk of nonsmokers for major vascular events.

If Mitigate matches this result and normalizes events, it will be a big deal and should change standard of care post-COVID. This in addition to addressing long COVID which is characterized by microvascular damage and chronic coagulation abnormalities.